The financials
Progyny, Inc. by the numbers
Progyny, Inc. (PGNY) reported revenue of $329M in Q1 2026 (quarter ended March 31, 2026), up 1.4% from the same quarter a year earlier. That came with a gross margin of 25% and net income of $24M (7.4% of revenue). For the full year FY2025, revenue was $1.29B (+10% year on year) and net income $59M. Its largest product in 2026-Q1 was Fertility Benefit Services at $209M, 64% of the disclosed total, just ahead of Pharmacy Benefit Services at 36%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $329M | $324M | +1.4% |
| Gross profit | $83M | $76M | +9.6% |
| Operating income | $35M | $24M | +46% |
| Net income | $24M | $15M | +61% |
| Diluted EPS | $0.29 | $0.17 | +71% |
| Product | Revenue | Share |
|---|---|---|
| Fertility Benefit Services | $209M | 64% |
| Pharmacy Benefit Services | $119M | 36% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $328.5M (+4.8%)
Fertility Benefit Services grew +1.5% year on yearPharmacy Benefit Services +1.2% year on year
Segment Latestquarter on quarteryear on year
- Fertility Benefit Services$209.4M$209.4MQoQ +3.7%year on year +1.5%+3.7%+1.5%
- Pharmacy Benefit Services$119.1M$119.1MQoQ +6.9%year on year +1.2%+6.9%+1.2%